Literature DB >> 2970872

Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status.

U Dianzani1, A Pileri, M Boccadoro, A Palumbo, P Pioppo, A Bianchi, A Camponi, G Fossati, S Battaglio, M Massaia.   

Abstract

The phenotypic pattern of peripheral blood T (PBT) lymphocytes was correlated with diagnosis and clinical status in 63 patients with monoclonal gammopathies (MGs). The numbers of lymphocytes expressing activation and CD11 determinants were significantly increased in suppressor/cytotoxic and helper/inducer subpopulations of patients with multiple myeloma (MM) and MG of undetermined significance (MGUS). The number of activated suppressor/cytotoxic cells was closely correlated with diagnosis and disease status. These cells were significantly higher in MM at diagnosis (160 +/- 88) than MGUS patients (61 +/- 79; P less than .01). Their number decreased to MGUS levels in MM in stable remission (58 +/- 53), but not in MM with tumor progression (172 +/- 102; P less than .001). In individual patients, part of these cells specifically adhered to dishes precoated with the related M-protein. No monoclonal T-beta gene rearrangement was detected in PBT and cytotoxic/suppressor subpopulations from two patients with a large proportion of activated cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2970872

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  Mechanisms of polyclonal hypogammaglobulinaemia in multiple myeloma (MM).

Authors:  M C Kyrtsonis; A Mouzaki; A Maniatis
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

2.  Deregulated cytokine network and defective Th1 immune response in multiple myeloma.

Authors:  M A Frassanito; A Cusmai; F Dammacco
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

3.  Defective interleukin-2 induction of lymphokine-activated killer (LAK) activity in peripheral blood T lymphocytes of patients with monoclonal gammopathies.

Authors:  M Massaia; A Bianchi; U Dianzani; A Camponi; C Attisano; M Boccadoro; A Pileri
Journal:  Clin Exp Immunol       Date:  1990-01       Impact factor: 4.330

4.  Use of cytoplasmic 5'nucleotidase for differentiating malignant from benign monoclonal gammopathies.

Authors:  G Majumdar; S E Heard; A K Singh
Journal:  J Clin Pathol       Date:  1990-11       Impact factor: 3.411

Review 5.  Idiotype-specific T cells in multiple myeloma: targets for an immunotherapeutic intervention?

Authors:  Q Yi; A Osterborg
Journal:  Med Oncol       Date:  1996-03       Impact factor: 3.064

6.  Generation of T cell clones binding F(ab')2 fragments of the idiotypic immunoglobulin in patients with monoclonal gammopathy.

Authors:  A Osterborg; M Masucci; S Bergenbrant; G Holm; A K Lefvert; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

7.  Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival.

Authors:  Martha Q Lacy; Sumithra Mandrekar; Angela Dispenzieri; Suzanne Hayman; Shaji Kumar; Francis Buadi; David Dingli; Mark Litzow; Peter Wettstein; Douglas Padley; Brian Kabat; Dennis Gastineau; S Vincent Rajkumar; Morie A Gertz
Journal:  Am J Hematol       Date:  2009-12       Impact factor: 10.047

8.  Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy.

Authors:  B C Millar; J B Bell; R L Powles
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.